Published in J Immunol on April 01, 2007
Sialic acids in human health and disease. Trends Mol Med (2008) 2.61
Pathogenic neisseriae: surface modulation, pathogenesis and infection control. Nat Rev Microbiol (2009) 1.87
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog (2010) 1.81
Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev (2010) 1.70
Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol (2010) 1.68
Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog (2011) 1.42
Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections. Front Microbiol (2011) 1.33
Meningococcal disease and the complement system. Virulence (2013) 1.19
Vaccines for gonorrhea: can we rise to the challenge? Front Microbiol (2011) 1.16
Sialic acids acquired by Pseudomonas aeruginosa are involved in reduced complement deposition and siglec mediated host-cell recognition. FEBS Lett (2009) 1.08
An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J Immunol (2010) 1.07
Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology (2008) 1.06
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev (2013) 1.05
Phosphoethanolamine residues on the lipid A moiety of Neisseria gonorrhoeae lipooligosaccharide modulate binding of complement inhibitors and resistance to complement killing. Infect Immun (2012) 1.05
The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol (2012) 1.04
Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun (2009) 1.04
Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. MBio (2013) 1.02
Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun (2012) 0.99
Factor H and neisserial pathogenesis. Vaccine (2008) 0.96
Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement. J Biol Chem (2011) 0.88
Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model. Infect Immun (2014) 0.86
Competition between antagonistic complement factors for a single protein on N. meningitidis rules disease susceptibility. Elife (2014) 0.85
Distinct binding and immunogenic properties of the gonococcal homologue of meningococcal factor h binding protein. PLoS Pathog (2013) 0.85
Molecular characterization of the interaction between sialylated Neisseria gonorrhoeae and factor H. J Biol Chem (2011) 0.83
A surface-exposed neuraminidase affects complement resistance and virulence of the oral spirochaete Treponema denticola. Mol Microbiol (2013) 0.81
Structure-function studies of the Neisseria gonorrhoeae major outer membrane porin. Infect Immun (2013) 0.80
The rickettsial OmpB β-peptide of Rickettsia conorii is sufficient to facilitate factor H-mediated serum resistance. Infect Immun (2012) 0.80
Factor H facilitates adherence of Neisseria gonorrhoeae to complement receptor 3 on eukaryotic cells. J Immunol (2010) 0.78
A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol (2016) 0.77
Saturating mutagenesis of an essential gene: a majority of the Neisseria gonorrhoeae major outer membrane porin (PorB) is mutable. J Bacteriol (2013) 0.76
Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology (2016) 0.75
The Phosphocarrier Protein HPr Contributes to Meningococcal Survival during Infection. PLoS One (2016) 0.75
Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol (2003) 14.80
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
Cardiovascular safety of tiotropium in patients with COPD. Chest (2009) 2.70
Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun (2008) 2.29
Vaginal swabs are appropriate specimens for diagnosis of genital tract infection with Chlamydia trachomatis. J Clin Microbiol (2003) 2.24
Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology (2002) 2.17
Genetic analysis of meningococci carried by children and young adults. J Infect Dis (2005) 2.12
Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis. Proc Natl Acad Sci U S A (2008) 2.06
Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis (2008) 2.00
Molecular analysis of bacteria in periodontitis: evaluation of clone libraries, novel phylotypes and putative pathogens. Microbiology (2003) 1.83
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog (2010) 1.81
Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerg Infect Dis (2006) 1.78
Interactions between Neisseria meningitidis and the complement system. Trends Microbiol (2007) 1.72
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine (2012) 1.71
Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev (2010) 1.70
A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol (2011) 1.68
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
Evolution of bacteriophages infecting encapsulated bacteria: lessons from Escherichia coli K1-specific phages. Mol Microbiol (2006) 1.60
Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J Clin Microbiol (2005) 1.56
Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem (2003) 1.55
Diagnostic potential of targeted electrical impedance scanning in classifying suspicious breast lesions. Invest Radiol (2002) 1.53
Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis (2013) 1.47
Simultaneous adrenal and extra-adrenal myelolipoma - an uncommon incident: case report and review of the literature. World J Surg Oncol (2008) 1.46
Distinct defensin profiles in Neisseria gonorrhoeae and Chlamydia trachomatis urethritis reveal novel epithelial cell-neutrophil interactions. Infect Immun (2005) 1.41
Target gene sequencing to characterize the penicillin G susceptibility of Neisseria meningitidis. Antimicrob Agents Chemother (2007) 1.40
Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol (2008) 1.39
Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol (2005) 1.38
A dual role of extracellular DNA during biofilm formation of Neisseria meningitidis. Mol Microbiol (2010) 1.35
The Lip lipoprotein from Neisseria gonorrhoeae stimulates cytokine release and NF-kappaB activation in epithelial cells in a Toll-like receptor 2-dependent manner. J Biol Chem (2003) 1.35
Phosphoethanolamine substitution of lipid A and resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides and complement-mediated killing by normal human serum. Infect Immun (2008) 1.32
The role of porins in neisserial pathogenesis and immunity. Trends Microbiol (2003) 1.30
Amino acid 310 determines the donor substrate specificity of serogroup W-135 and Y capsule polymerases of Neisseria meningitidis. Mol Microbiol (2008) 1.26
Role of complement in defense of the middle ear revealed by restoring the virulence of nontypeable Haemophilus influenzae siaB mutants. Infect Immun (2006) 1.25
Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso. J Infect Dis (2007) 1.23
Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res (2008) 1.23
Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat (2006) 1.22
Implications of phase variation of a gene (pgtA) encoding a pilin galactosyl transferase in gonococcal pathogenesis. J Exp Med (2002) 1.22
Identification of the hypervirulent lineages of Neisseria meningitidis, the ST-8 and ST-11 complexes, by using monoclonal antibodies specific to NmeDI. J Clin Microbiol (2003) 1.22
Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci U S A (2005) 1.20
Genetics of capsule O-acetylation in serogroup C, W-135 and Y meningococci. Mol Microbiol (2004) 1.19
The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog (2012) 1.17
PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging (2004) 1.17
IS1301 fingerprint analysis of Neisseria meningitidis strains belonging to the ET-15 clone. J Clin Microbiol (2006) 1.16
Clinical and epidemiological correlates of genotypes within the Mycobacterium avium complex defined by restriction and sequence analysis of hsp65. J Clin Microbiol (2002) 1.15
The ArcA regulon and oxidative stress resistance in Haemophilus influenzae. Mol Microbiol (2007) 1.14
Biochemical characterization of a Neisseria meningitidis polysialyltransferase reveals novel functional motifs in bacterial sialyltransferases. Mol Microbiol (2007) 1.13
Virulence evolution of the human pathogen Neisseria meningitidis by recombination in the core and accessory genome. PLoS One (2011) 1.12
EpiScanGIS: an online geographic surveillance system for meningococcal disease. Int J Health Geogr (2008) 1.11
Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade. Infect Immun (2006) 1.10
Role of complement in host defense against pneumococcal otitis media. Infect Immun (2009) 1.09
An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J Immunol (2010) 1.07
Relative contributions of dectin-1 and complement to immune responses to particulate β-glucans. J Immunol (2012) 1.07
Characterization of Escherichia coli isolates from hospital inpatients or outpatients with urinary tract infection. J Clin Microbiol (2013) 1.07
Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res (2008) 1.07
Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect Immun (2011) 1.06
lgtC expression modulates resistance to C4b deposition on an invasive nontypeable Haemophilus influenzae. J Immunol (2007) 1.06
Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Immunol Lett (2007) 1.06
Meningococcal biofilm formation: structure, development and phenotypes in a standardized continuous flow system. Mol Microbiol (2006) 1.06
Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol (2012) 1.06
Phosphoethanolamine residues on the lipid A moiety of Neisseria gonorrhoeae lipooligosaccharide modulate binding of complement inhibitors and resistance to complement killing. Infect Immun (2012) 1.05
In vitro resistance mechanisms of Neisseria meningitidis against neutrophil extracellular traps. Mol Microbiol (2013) 1.04
The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol (2012) 1.04
Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun (2009) 1.04
A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm (2013) 1.03
Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect Immun (2007) 1.03
Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. MBio (2013) 1.02
Killing of dsrA mutants of Haemophilus ducreyi by normal human serum occurs via the classical complement pathway and is initiated by immunoglobulin M binding. Infect Immun (2005) 1.02
Microbiological evaluation of the new VITEK 2 Neisseria-Haemophilus identification card. J Clin Microbiol (2007) 1.00
Depressive symptoms and sexual risk behavior in young, chlamydia-infected, heterosexual dyads. J Adolesc Health (2009) 1.00
Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol (2012) 0.99
Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. MBio (2011) 0.99
Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins. J Immunol (2011) 0.99